The Latest Breaking News from Pfizer Inc

Although inflation moderated for the sixth consecutive month in December, a recession is still likely as the Fed is expected to keep raising rates this year. Amid an uncertain economic backdrop, fundamentally strong and popular stocks on Wall Street, Microsoft (MSFT), Pfizer (PFE), and AT&T (T), could make ideal additions…

While inflation has been showing signs of cooling recently, it is still far beyond the Fed’s target rate. Consequently, the Fed is expected to keep raising the interest rates for some time, fueling the chances of a global recession. Therefore, it could be wise to invest in well-performing stocks Pfizer…

Despite rampant market volatility, Goldman Sachs expects the U.S. economy to avoid a recession. However, as uncertainties remain, medical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY), which pay reliable dividends, could be ideal buys to ensure a steady income stream. Keep reading….

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Moreover, healthcare is considered relatively resilient amid market downturns. So, given the economic uncertainties, investors could consider buying quality pharmaceutical stocks such as Pfizer (PFE), Novartis (NVS), and Bristol-Myers Squibb (BMY) this…

Along with an interest rate hike of 50 bps at the FOMC meeting last week, the Fed officials signaled to continue raising rates through next year, with no expectations to cut rates until 2024. The Fed’s hawkish stance and rising recessionary fears have dampened investor sentiment lately. Given the backdrop,…

The Fed announced a 50-bps rate hike this week, stepping down from its 75-bps raises for four consecutive times. With cooling inflation and reduced interest rate hikes, the economy might succeed in avoiding a recession. However, as the market conditions are expected to remain uncertain with the Fed intending to…

Pfizer Inc. cemented a deal first announced in March to sell its antiviral medication Paxlovid in China through a state-owned company, adding to supply of COVID treatments in the country that’s now facing a massive infection surge.

With the Labor Department reporting slower inflation in November and optimism about a reduced magnitude of interest rate hikes, investors are anxiously awaiting a year-end rally. Therefore, fundamentally strong stocks Pfizer (PFE), Murphy USA (MUSA), and Berry Corporation (BRY) could be solid investments now. Keep reading….

Pfizer (PFE) benefited substantially from the COVID-19 pandemic. It pays a more than 3% dividend, making it attractive for investors looking for stable income. The stock has picked up steady momentum, and its robust fundamentals should help the company easily outpace the market in the coming years. Let’s discuss this…